Background-Treatment eligibility rates in patients with HCV monoinfection have not been directly compared with patients with HCV/HIV coinfection. These data are important for planning interventions to optimize HCV management.
INTRODUCTION
The current standard of care for chronic hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, which can lead to viral eradication and halt or regress HCV-associated hepatic fibrosis. With this pharmacotherapy, sustained virologic response rates are 54%-56% among HCV monoinfected persons and 27%-40% in HCV/HIV-coinfected persons. [1] [2] [3] [4] [5] Despite substantial improvements in HCV therapy over the last 20 years, only a minority of HCV-infected persons are ever prescribed treatment, [6] [7] [8] [9] perhaps due to lack of treatment eligibility, presence of contraindications to therapy, and/or perceived and real issues with adherence to the medications and follow-up visits in this population. Previous studies on HCV treatment eligibility and contraindications identified nonadherence and medical, psychiatric, and substance abuse comorbidities as the major reasons for nontreatment. [10] [11] [12] [13] [14] [15] Poor communication of information by providers and a perception of being misled, misinformed, or stigmatized were also reported by HCV-infected patients attending a specialty care clinic. 16 Among HCV-infected veterans, rates of HCV treatment are lower in HCV/HIV-coinfected persons compared with HCV-monoinfected persons. 10 However, there are scant data comparing treatment eligibility and contraindications directly between HCV-monoinfected and HCV/HIV-coinfected persons. These data are important for identifying the most common comorbidities that preclude HCV therapy and that should be addressed prior to treatment. In addition, such results may also suggest future interventions that could be undertaken to improve prescription rates for HCV therapy, which may help lower the incidence of HCV-associated liver failure in the HCV-monoinfected and HCV/HIV-coinfected populations. To address these issues, we compared HCV treatment eligibility in HCV-monoinfected versus HCV/HIVcoinfected persons in an academic medical center setting.
METHOD
We prospectively recruited adult HCV-monoinfected and HCV/HIV-coinfected patients referred for HCV care at the Infectious Diseases/HIV Clinics and Hepatology Clinics at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania; University of Pennsylvania Medical Center in Philadelphia, Pennsylvania; and the University of Cincinnati Medical Center in Cincinnati, Ohio. After providing informed consent, all subjects were interviewed using a uniform structured questionnaire to gather information on demographics, risk factors for HCV and HIV, comorbid illnesses, family history, substance abuse (tobacco, alcohol, and illicit drugs), educational status, history of incarceration, and number of lifetime sexual partners. Additional laboratory and clinical data were abstracted from the subjects' medical records at the initial and most recent visits for HCV care. Liver biopsy data were retrieved from hospital computerized pathology records. HCV treatment information was gathered from patient self-report and confirmed by chart and/or pharmacy records review. All clinic patients who presented to each of the participating sites between January 2005 and November 2006 were eligible for inclusion and were recruited consecutively based on the inclusion and exclusion criteria listed above. The study was approved by the institutional review boards of the University of Pittsburgh (ClinicalTrials.gov identifier NCT00222859 for University of Pittsburgh), University of Pennsylvania, and University of Cincinnati.
HCV treatment eligibility and contraindications represented the main study outcomes. Criteria for eligibility and contraindications to HCV treatment were derived from current practice guidelines. [17] [18] [19] The operational de nitions of comorbidities and contraindications are provided in Table 1 . HCV treatment eligibility and contraindications were determined at the time of initial visit for HCV care. Subjects were considered to be eligible for HCV therapy and/or have a contraindication to HCV treatment per self-report or per the medical record. Additionally, evidence of liver injury was defined as a serum alanine aminotransferase (ALT) level above the upper limit of normal as reported by each laboratory or a liver biopsy showing at least stage 2 fibrosis. Baseline subject characteristics were described by using means and standard deviations for continuous data and proportions for categorical data. Differences between groups were assessed by using t tests or Wilcoxon rank-sum tests, as appropriate, for continuous data and chi-square tests for categorical data. Analyses were conducted using STATA ® statistical software (Stata Corp., College Station, Texas, USA).
We conducted analyses on all subjects seen at the sites as well as on the subgroup who had never received HCV treatment. Because liver biopsy is the gold standard to determine the extent of liver injury, we also determined the contraindications in the subgroup of subjects who had evidence of liver injury on a liver biopsy prior to treatment.
RESULTS
We recruited 399 subjects, 241 (60%) of whom were HCV monoinfected and 158 (40%) were HCV/HIV coinfected. HCV/HIV-coinfected subjects were more likely to be male, African American, and have a lower body mass index than HCV-monoinfected subjects ( Table 2 ). In addition, HCV/HIV-coinfected subjects were less likely to have undergone liver biopsy (43.7% vs. 71.4%, p < .001) or to have ever received HCV treatment (32.3% vs. 62.2%, p < .001) ( Table 2) .
HCV/HIV-coinfected persons were less likely to have a positive HCV RNA (70.9% vs. 81.3%, p = .03), but within this group a similar number had evidence of liver injury (87.5% vs. 85.7%, p = .09) ( Table 3 ). They were also more likely to have at least one contraindication for treatment (81.6% vs. 64.9%, p = .004). In particular, ongoing alcohol abuse and depression were significantly more likely to be present in the HCV/HIV-coinfected compared with the HCVmonoinfected subjects.
When analyses were limited to subjects who had never been prescribed HCV treatment, the baseline characteristics showed the same patterns as with the full dataset. HCV/HIV-coinfected subjects were more likely to be African American (62.6% vs. 40.7%, p = .006) and male (80.4% vs. 53.8%, p < .001) and were less likely to have undergone liver biopsy (29.9% vs. 44%, p = .04). As in the full dataset, HCV/HIV-coinfected subjects were less likely to be HCV RNA positive (64.5% vs. 78.0%, p = .04), but rates of liver injury were not significantly different from those in HCV-monoinfected subjects (88.4% vs. 88.7%, p = .1). HCV/HIV-coinfected subjects were more likely to have depression and tended to have higher rates of ongoing alcohol abuse compared with HCV-monoinfected persons. We also performed analysis limited to subjects with a liver biopsy and who had evidence of liver injury on a liver biopsy (either the inflammation or fibrosis score ≥ 2); the results were similar to the overall group, except that the differences in certain contraindications did not reach statistical significance due to a smaller sample size.
A flowchart of treatment indications and contraindications is presented in Figure 1 for the overall group and in Figure 2 for the subset who had never received any treatment.
DISCUSSION
Although effective treatment for HCV is now available and leads to eradication of chronic infection in a substantial number of treated patients, this population poses special challenges due to the higher prevalence of certain medical, psychiatric, and substance abuse comorbidities. 20 However, there are scant data directly comparing the rates of treatment eligibility and contraindication in HCV/HIV-coinfected persons versus HCV-monoinfected persons in academic medical center settings. Our study compares these two groups in an academic medical center setting.
Previous studies have shown that HCV/HIV coinfected subjects are less likely to be prescribed HCV treatment, but the studies had a smaller sample size or the presence of treatment indications was not taken into account. 8, 10 Our results provide evidence that HCV/HIVcoinfected subjects are less likely to be eligible for HCV therapy based on current treatment guidelines compared with HCV monoinfected subjects. The HCV/HIV-coinfected subjects in our study had a lower rate of chronic HCV infection (defined as HCV antibody positive, HCV RNA positive) than the HCV-monoinfected group, so fewer coinfected subjects warranted HCV therapy. This is in contrast with previous studies that have suggested that spontaneous HCV clearance occurs in only 10% of HCV/HIV-coinfected persons and even less frequently in those with CD4 counts less than 200 cells/mm. 3, 21 The reasons for the low rate of chronic HCV infection among coinfected subjects in our study is unclear.
Our study also demonstrates that HCV/HIV coinfected subjects are more likely to have at least one treatment contraindication present compared with HCV-monoinfected persons. Contraindications more prevalent in the HCV/HIV-coinfected persons in our study included depression and alcohol abuse. Depression and substance abuse have been previously reported to be more common in HCV-infected compared with HCV-uninfected persons and in HIVinfected persons compared with HIV-uninfected persons. 7, 22, 23 However, our study demonstrates and compares these comorbidities directly among HCV-infected patients cared for in tertiary care referral centers. Of note, rates of contraindications to HCV therapy due to hematological abnormalities (anemia, thrombocytopenia) were less common in the coinfected group. A possible explanation of this is referral bias, whereby persons with such toxicities are not evaluated. Additionally, HIV-infected persons may be more likely to be treated with hematopoietic growth factors for such abnormalities. We did not evaluate the use of growth factors in our study. Nevertheless, practitioners managing HCV/HIV-coinfected patients should be aware of the more rapid declines in hemoglobin concentration in patients being treated with both ribavirin and zidovudine 24 and should consider switching to an alternative nucleoside analogue prior to the initiating anti-HCV therapy.
Our findings that HCV/HIV-coinfected persons are less likely to be eligible for HCV therapy and are more likely to have treatment contraindications compared with HCV-monoinfected subjects have important clinical implications. Because chronic HCV is highly prevalent among HIV-infected patients and progresses rapidly to end-stage liver disease in the presence of HIV, antiviral therapy is critical for long-term survival of patients coinfected with HCV/HIV. However, it is clear from our study why coinfected patients who might be at high risk for liver failure do not receive such potentially lifesaving therapy. Methods aimed at identifying these high-risk patients prior to end-stage liver disease development (i.e., in time for patients to benefit most from treatment) may help clinicians target HCV therapy to this group and convince more HCV/HIV-coinfected patients who need HCV treatment to accept it. In addition, our findings are important in planning interventions for optimal management of HCV infection in these groups, as they provide information about which comorbidities should be addressed aggressively if treatment rates for HCV are to be improved in these populations. The addition of dedicated mental health professionals and substance abuse counselors and treatment providers may enhance eventual treatment eligibility rates in these populations.
Our study has the strength of being able to be generalized to patient populations treated at tertiary care academic medical centers. The data were gathered prospectively to specifically answer questions about treatment eligibility and rates of prescription of treatment. Data were gathered uniformly by experienced investigators. On the other hand, a limitation of our study is that the study population constituted a referral population and is not representative of the general population with HCV infection. Using a study population from tertiary care referral centers biases the results toward sicker patients or patients who have already been identified as needing treatment for HCV. Additionally, it is possible that patients with major contraindications were not referred for evaluation and treatment at all. We used histologic abnormalities on the liver biopsy and elevations of hepatic transaminase levels as markers of liver injury to determine eligibility for treatment. It is well known that patients with normal hepatic transaminase levels may have significant abnormalities on liver histology. Many centers have also started using noninvasive markers of liver fibrosis in the evaluation of HCVinfected patients to determine the presence of liver injury.
We chose contraindications to treatment based on the current treatment guidelines. It should be noted that not all contraindications are absolute, and indeed many may change over time (e.g., anemia may be treated, depression may resolve with or without treatment, etc.). Our definition takes the most conservative view of the treatment indications; even with such conservative estimates, we found the treatment prescription rates to be very low among eligible subjects in both HCV-monoinfected and HCV/HIV-coinfected groups. We did not analyze subjects who refused to participate in the study, because no data were gathered on those subjects.
In summary, HCV/HIV-coinfected persons are less likely to be eligible for HCV therapy and more likely to have HCV treatment contraindications. Strategies to manage modifiable comorbidities that constitute contraindications to HCV treatment may enhance treatment rates for HCV. Flowchart of treatment eligibility and contraindications among HCV-monoinfected and HCV/ HIV-coinfected subjects in the study with no prior history of HCV treatment. Baseline characteristics of subjects enrolled in the study. Treatment eligibility and contraindications in HCV monoinfected vs. HCV-HIV coinfected subjects. Note: HCV= hepatitis C virus.
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a Alcohol use more than once a week.
b Defined as pretreatment hemoglobin ≤13 g/dL for men and ≤12 mg/dL for women.
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